Nexi-002 T Cells
Relapsed Refractory Multiple Myeloma
NexImmune Inc.Cell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
498 Active assets in the Relapsed Refractory Multiple Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
Inno-206 University of Arkansas | Phase 3 | BBB |
Hyaluronidase fihj Massachusetts General Hospital | Phase 4 | BBB |
Busulphan M.D. Anderson Cancer Center | Phase 4 | BBB |
Filanesib PETHEMA Foundation | Phase 2 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →